Clinical Chemistry Analyzers Market Size to Worth USD 24.8 BN by 2032

According to Precedence Research, the global clinical chemistry analyzers market size is expected to be worth around USD 24.8 billion by 2032 and expanding growth at a CAGR of 5.42% from 2023 to 2032.


Ottawa, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The global clinical chemistry analyzers market size was valued at USD 14.63 billion in 2022. The advancement of the technologies behind clinical chemistry analyzers, an increase in the number of people worldwide who are getting older, advances in point-of-care testing technology, and the growing allure of laboratory mechanization are the main factors contributing to the growth of the global clinical chemistry analyzers market. The research provides a thorough analysis of the market's key segments, trends, drivers, restraints, competitive environment, and other important elements.

Ask here for sample pdf@

Regional snapshots

The region is anticipated to maintain its leadership during the projected period. North America now accounts for the greatest portion of the global market. Due to the continued necessity for routine diagnostic procedures, there is expected to be a considerable need for clinical chemistry analyzers. The rising prevalence of diseases like cancer and diabetes, aging populations, and increased public awareness of preventative medicine make such a technique necessary. In addition, rising demand for more pricey automated clinical chemistry systems is anticipated to support market expansion.

Report highlights

  • Reagents dominated the market with highest share in product category in 2022. The industry's large supply of reagents, which are available to satisfy a range of clinical needs, is projected to be the cause of the sizeable market share. Enzymes, substrates, specific proteins, electrolytes, lipids, and other substances are the main components of these reagents, which are necessary to achieve accurate findings in analytical procedures.
  • The prevalence of lifestyle-related diseases including obesity and other metabolic abnormalities is also on the rise, and in 2021, Basic Metabolic Panel (BMP) maintained a highest share of the test market. The growing importance and awareness of point-of-care testing is a crucial factor in the sector share. BMP is a group of examinations that provide medical examiners with clinical information regarding problems caused by chemical imbalances in the body.
  • Hospitals led the end-use category with largest share in 2022 because of their massive sample sizes, high readmission rates, and high patient numbers. Supportive infrastructure, which enables successful diagnostic operations, also contributes to the growth of hospitals segment.

Customize this study as per your requirement -

Scope of this report

Market Size in 2030USD 22,320 Million
CAGR5.42% from 2023 to 2032
Largest Revenue HolderNorth America
Fastest Growing RegionAsia Pacific
Key PlayersAbbott Laboratories, Danaher Corporation (Beckman Coulter, Inc.), Hoffmann-La Roche Ltd., Horiba, Ltd., Johnson & Johnson, Elitech Group, Mindray Medical International Limited, Siemens Healthcare Private Limited, Sysmex Corporation, Thermo Fisher Scientific Inc. and Others

Market Dynamics


An increase in the number of chronic diseases is expected to contribute to the expansion of the market. The report of GLOBOCAN 2020 estimates that approximately 19,292,789 new suspects of cancer will arise worldwide by 2020. Around 2040, the number of cases is expected to increase to 28,887,940 instances, as per estimates. Additionally, according to the International Diabetes Federation's Tenth Diabetes Atlas Edition 2021, there were 537 million individuals with diabetes worldwide in 2021, according to projections, there will be 643 million people in the world by 2030 which will be 783 million by 2045.

Additionally, the market is experiencing an expansion probably by the product launches of the key market competitors. The point-of-care (POC) i20 fluorescence-based chemistry analysis system and CO-OX blood gas, for example, was launched by EDAN Instruments, in July 2022. It could examine around 45 parameters, ranging from blood gases to electrolytes to CO-oximetry. These product introductions are estimated to boost the market's expansion during the forecast period.


Clinical chemistry analyzers' technological advancements come at a high cost. As clinical analyzers become more automated and integrated, analyzer prices are rising. High-priced devices are unaffordable for laboratories. Therefore, tools that are affordable and simple to use are required. High instrument costs can lead to higher testing costs, which could limit the growth of the global market for clinical chemistry analyzers over the forecast period. The increasing number of patients suffering from chronic diseases has boosted the number of laboratory tests that are carried out all over the world. This has also boosted the demand for skilled laboratory technicians and assistants.

The gap which has been created by the absence of pathologists and laboratory technicians globally has emerged as one of the major restraining factors for the growth of the clinical chemistry analyzer market. The absence of skilled technicians and pathologists hinders the results that are obtained from the laboratories. This flaw in the system hampers the final treatment of the patients. These factors have hindered the growth of the market.


It is projected that the market players will benefit greatly from the implementation of advantageous government initiatives, programs, and finance that assist the growth of labs and diagnostics. The market is estimated to have several expansion opportunities throughout the projected period because of the aforementioned factors, raising market size. Management of chronic diseases will help to generate new opportunities for the clinical chemistry analyzers market. Multiple prescriptions are provided by doctors for conducting various laboratory tests that will help to produce a suitable diagnosis for the patient. An increasing number of blood tests for confirmation of the diagnosis helps the market to record a considerable revenue. The increasing trend of preventive medicine will also emerge as a great opportunity for the market.


Additionally, it is predicted that increasing government programs and financing for preventative care will present chances for the development of the clinical chemistry analyzer market in the upcoming years. In order to conduct various research and development programs, huge investments are required to be made by the key market players. The market faces a great challenge where the developing and underdeveloped nations are concerned. The individual practitioners, physicians’ offices and most of the small laboratories cannot afford such analyzers, which proves to be a challenge for the growth of the market. The high cost associated with the research and development programs of clinical chemical analyzers emerges as one of the major challenges for the growth of the market in the long run. The lack of skilled technicians and laboratory assistants has hindered the growth of the market to a great extent.

Recent Developments

  • For developing the urine analysis solutions, Sysmex made an investment in Astrego Diagnostics in 2020. 
  • In 2017, Viewics (US) was acquired by Roche Diagnostics for the expansion of its market and to hold a leading position.

Market Segmentation

By Product 

  • Analyzers
    • Small
    • Medium
    • Large
    • Very Large
  • Reagents
    • Calibrators
    • Controls
    • Standards
    • Others
  • Others

By Test

  • Basic Metabolic Panel
  • Electrolyte Panel
  • Liver Panel
  • Lipid Profile
  • Renal Profile
  • Thyroid Function Panel
  • Specialty Chemical Tests

By End-Use

  • Hospitals
  • Academic Research Centers
  • Diagnostic Laboratories
  • Others

By Geography

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa (MEA)

Immediate Delivery Available | Buy This Premium Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333

About Us

Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us: